ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

JUNE 2022

NEW & REOPENED TRIALS HIGHLIGHTED IN GREEN!

- JUST IN TIME TRIALS (JIT)
- AML
- ANAL
- ALL
- APL
- BLADDER-UROTHELIAL
- BRAIN
- BREAST/ GYN
- CANCER CONTROL
- CLL
- CML
- COLON-RECTAL
- ESOPHAGEAL - GASTRIC
- HEAD & NECK
- LYMPHOMA
- MDS
- MELANOMA
- MERKEL
- MOLECULAR STUDIES
- MULTIPLE MYELOMA
- NEUROENDOCRINE
- NSCLC
- PANCREATIC
- PROSTATE
- RADIATION TRIALS
- RENAL CELL
- SMALL CELL LUNG CANCER

Updated 6.23.22

RADIATION LOCATIONS:
OSF Glen Oak - OSF main hospital
OSF Route 91 (attached to Illinois CancerCare)
UPHM - Unity Point Health Methodist
Galesburg - Western Illinois Cancer Treatment Center

ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

MENU

JUNE 2022

JUST IN TIME (JIT) *TRIALS*	***Contact Disease Specific Navigator**
Multi-Disease Site: Advanced/Metastatic Solid Tumors	
RAIN-3202	A Phase 2 Basket Study of Milademetan in Advanced/Metastatic Solid Tumors
Brain	
A071702	A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent Glioblastoma
Carcinoid	
S2104	Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
Endometrial	
GY014	*(Temp. suspended)* Phase II Study of Tazemetostat (EPZ-6438) (IND # 138671) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
Gastrointestinal	
EA2187	*Temporarily closed* Phase II study of Pevonedistat in Combincatoin with Carbo and paclitaxel in advanced intrahepatic cholangiocarcinoma.
Genitourinary - Rare	
A031702	Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors *(temp closed cohorts - small cell carcinoma/neuroendorine & adenocarcinoma of bladder, penile, and misc GU tract variants, renal medullary carcinoma, and rare GU)*
Head & Neck	
EA3191	**Temporarily Closed (RT at Route-91)** A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features
Lung	

S1934	Randomized Phase II Trial of Trimodality +/- Atezolizumab in Resectable Superior Sulcus Non-Small Cell Lung Cancer. **NASSIST** (Neoadjuvant Chemoradiation +/- Immunotherapy Before Surgery for Superior Sulcus Tumors)
Multi-Disease	
S1614	*(temp closed)* A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or past hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors
Ovarian	
GY014	*(temp closed)* Phase II Study of Tazemetostat (EPZ-6438) (IND # 138671) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
Pancreas	
S2001	Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations
S2104	Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
Rectal	
EA2201	**(RT at Glen Oak, UPHM, Galesburg)** A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma
Sarcoma	
A091902	A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma *(closed to taxane pre-treated pts only)*
Skin	
A091802	Phase II randomized Trial of Avelumab plus cetuximab versus avelumab alone in advanced cutaneous Squamous cell carcinoma of skin
Thymoma	
S1701	A Randomized Phase II Trial of Carboplatin-Paclitaxel with or without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma

ILLINOIS CANCERCARE, P.C.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

JUNE 2022

MENU

AML

Navigator - Heather x3661

ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

JUNE 2022

MENU

ANAL

Navigator - Carrie x3621

EA2176	A Randomized Phase III Study of Immune Checkpoint Inhibition With Chemotherapy in Treatment-Naive Metastatic Anal Cancer Patients
EA2182	**(RT at UPHM and Glen Oak)** A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)

ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

JUNE 2022

MENU

APL

Navigator - Heather x3661

There are no trials available at this time

ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

JUNE 2022

MENU

ACUTE LYMPHOBLASTIC LEUKEMIA

Navigator - Heather x3661

EA9152	**Temporarily Closed** | A Phase IB/II Study of Venetoclax (ABT-199) in Combination With Liposomal Vincristine in Patients With Relapsed or Refractory T-Cell or B-Cell Acute Lymphoblastic Leukemia

ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

JUNE 2022

MENU

BLADDER / UROTHELIAL

Navigator - Carrie x3621

	ADJUVANT / NEOADJUVANT
BMS CA017-078	**(Peoria, Bloomington, Galesburg, and Peru)** -A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer (*BMS-986205/placebo tablets discontinued*)
EA8185	**(RT pending at Glen Oak & Rt-91)** Phase 2 Study of Bladder-Sparing Chemoradiation With MEDI4736 (Durvalumab) in Clinical Stage 3, Node Positive Bladder Cancer (INSPIRE)
S1806	**(RT at Glen Oak, UPHM and Galesburg)** Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer
S2011	Randomized Phase II Trial of Gemcitabine, Avelumab and Carboplatin vs. No Neoadjuvant Therapy Preceding Surgery for Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma: SWOG GAP TRIAL
	METASTATIC
A031901	Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial
A032001	Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum-Based Chemotherapy in Patients With Metastatic Urothelial Cancer

A032002	**(RT at Glen Oak)** Phase II Randomized Trial of Atezolizumab Versus Atezolizumab and Radiation Therapy for Platinum Ineligible/Refractory Metastatic Urothelial Cancer (ART)

ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

JUNE 2022

MENU

BRAIN

Navigator - Carrie x3621

BN007	**Temporarily Closed (RT at UPHM, Glen Oak, Galesburg)** A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
BN011	**(RT credentialing pending)** A Phase III Trial of Gleostine® (Lomustine)-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients With Methylated MGMT Promoter Glioblastoma
N0577	**(RT at Glen Oak, RT 91, and UPHM)** Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma

ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

JUNE 2022

MENU

BREAST

Navigator - Angie x3613

DCIS	
AFT-25	Comparing an Operation to Monitoring, With or Without Endocrine Therapy Trial For Low Risk DCIS: A Phase III Prospective Randomized Trial **(COMET)**
NEO/ADJUVANT TREATMENT	
Neo/Adjuvant - HER2 Positive	
EA1181	Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response (CompassHER2-pCR)
Neo/Adjuvant - Hormone Receptor Positive / HER2 Negative	
BR007	**(RT at Galesburg, Glen Oak, Rt 91, UPHM)** Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer
Neo/Adjuvant - Triple Negative	
METASTATIC TREATMENT	
Metastatic - HER2 Positive	
Metastatic - Hormone Receptor Positive / HER2 Negative	
Metastatic - Triple Negative	
SURGERY / RADIATION ONLY	
A011202	**Temporarily Closed**- A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in breast Cancer Patients (cT1-3 N1) Who Have Positive Lymph Node Disease After Neoadjuvant Chemotherapy. ***(RT: Glen Oak, Rt 91, UPHM, Galesburg)***
MA.39	Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer ***(RT: Glen Oak and UPHM)***
CANCER CONTROL (Breast only)	
A191901	**(Peoria, Bloomington, Galesburg, Ottawa, Pekin, and Peru)** Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions *(only enrolling African American women)*

A211901	Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions
A222004	A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia
EAQ202	Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
S1912CD	A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)
S2013	**(Peoria, Bloomington, Galesburg, Pekin, Washington**) Immune Checkpoint Inhibitor Toxicity: A Prospective Observational Study **(I-CHECKIT)**
URCC 16070	Treatment of Refractory Nausea- for breast cancer patients.
URCC-18007	Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue in stage I-III Breast cancer pts.- *at least 2 months out from surgery/tx/radiation*
URCC 21038	**(Peoria Only)** Disparities in Results of ImmuneCheckpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated With anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting
WF-1901	Internet-delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS)

GYNECOLOGICAL

Navigator - Angie x3613

NRG - GY023	A Randomized Phase II Trial of Triplet Therapy (a PD-L1 Inhibitor (Durvalumab) MEDI4736 in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or (Durvalumab) MEDI4736 and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab

ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

MENU

JUNE 2022

Navigators - Courtney x3660
Hannah x3603
Kelsey x 3618

CANCER CONTROL

MULTI-DISEASE SITES

A211901	Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions
A222004	A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia
EAQ202	Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
S1912CD	A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)
S2013	**(Peoria, Bloomington, Galesburg, Pekin, Washington)** Immune Checkpoint Inhibitor Toxicity: A Prospective Observational Study **(I-CHECKIT)**
URCC 21038	**(Peoria only)** Disparities in Results of ImmuneCheckpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated With anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting
WF-1901	Internet-delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS)

BREAST

A191901	**(Peoria, Bloomington, Galesburg, Ottawa, Pekin, and Peru)** Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions *(only enrolling African American women)*
URCC 16070	Treatment of Refractory Nausea- for breast cancer patients.
URCC-18007	Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue in stage I-III Breast cancer pts.- *at least 2 months out from surgery/tx/radiation*

LUNG

	Nothing currently available for Lung only - ***See Multi-Disease Cancer Control trials ABOVE .***

COLORECTAL

A221805	Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
WF-1806	(M&M Study) Myopenia and Mechanisms of Chemotherapy Toxicity in older Adults with Colorectal Cancer

BRAIN

WF-1801	A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy

REGISTRY

Contact Disease Specific Navigator

NHLBI-MDS	**(Peoria, Bloomington and Galesburg only)** -The National Myelodysplastic Syndromes (MDS) Study

ILLINOIS CANCERCARE, P.C.

Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

JUNE 2022

MENU

Navigator - Ashton x3611
Carrie x3621

CARCINOID

No trials at this time

ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

JUNE 2022

MENU

CLL

Navigator - Heather x3661

1st Line

A041702	Temporarily closed | A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)

2nd Line, 3rd Line, etc.

no trials at this time

ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

JUNE 2022

MENU

CML

Navigator - Heather x3661

ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

JUNE 2022

MENU

COLON / RECTAL

Navigator - Carrie x3621

	Adjuvant
A021502	Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
C-14	Second Colorectal Cancer Clinical Validation Study to Predict Recurrence Using A Circulating Tumor DNA Assay To Detect Minimal Residual Disease **(CORRECT-MRD II)**
GI005	Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA)
GI008	**REOPENED** Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
	Metastatic
MK 7339-003	**(Peoria, Bloomington, Galesburg, Peru)** A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab with 5-FU in Participants with Unresectable or Metastatic Colorectal Cancer who Have Not Progressed Following First-line Induction of FOLFOX With Bevacizumab (LYNK-003)
	CANCER CONTROL (Colorectal only)
A211901	Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions
A221805	Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
A222004	A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia
EAQ202	Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
S1912CD	A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)
S2013	**(Peoria, Bloomington, Galesburg, Pekin, Washington)** Immune Checkpoint Inhibitor Toxicity: A Prospective Observational Study **(I-CHECKIT)**
URCC 21038	**(Peoria Only)** Disparities in Results of ImmuneCheckpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated With anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting

WF-1901	Internet-delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS)
WF-1806	(M&M Study) Myopenia and Mechanisms of Chemotherapy Toxicity in older Adults with Colorectal Cancer

ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

JUNE 2022

MENU

ESOPHAGEAL- GASTRIC	Navigator - Carrie x3621
EA2174	**(RT at Glen Oak, RT-91, UPHM, Galesburg)** A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma

ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

JUNE 2022

MENU

HEAD & NECK

Navigator - Ashton x3611

EA3161	**(RT at Glen Oak, UPH, Galesburg)** A Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
EA3191 - JIT	**Temporarily Closed** **(RT at Route-91)** A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features
HN005	**(RT at UPHM, Galesburg, Glen Oak)** A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
HN009	**(RT at UPHM)** Randomized Phase II/III Trial of Radiation With High-Dose Cisplatin (100 mg/m2) Every Three Weeks Versus Radiation With Low-Dose Weekly Cisplatin (40 mg/m2) for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)

ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

JUNE 2022

MENU

Navigator - Heather x3661

LYMPHOMA

	HL
S1826	**(RT at Glen Oak, Rt-91, UPHM)** A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
	NHL
EA4181	A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients ≤ 70 Years Old With Untreated Mantle Cell Lymphoma
	SLL

ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

JUNE 2022

MENU

MDS

Navigator - Heather x3661

NHLBI-MDS	**(Peoria, Bloomington and Galesburg only)** -The National Myelodysplastic Syndromes (MDS) Study

ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

JUNE 2022

MENU

MELANOMA

Navigator - Carrie x3621

CA224098	A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Metastatic or Unresectable Melanoma

ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

JUNE 2022

MENU

MERKEL

Navigator - Carrie x3621

EA6174	**(RT at Glen Oak, UPHM, Galesburg)** A Phase III Randomized Trial Comparing Adjuvant MK3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma

ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

JUNE 2022

MENU

MOLECULAR STUDIES

***Contact Disease Specifc Navigator**

64091742PCR0002 / Prevalence	Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer **(Prevelence)**
A151804	Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
NSABP C-14	Second Colorectal Cancer Clinical Validation Study to Predict Recurrence Using A Circulating Tumor DNA Assay To Detect Minimal Residual Disease **(CORRECT-MRD II)**
S1823	A Study of miRNA 371 in Patients With Germ Cell Tumor *(closed to high risk pts or pts on chemo for testicular cancer)*
TPX-0005-01 (TRIDENT-1)	A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with **Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements** (TRIDENT-1)

ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

JUNE 2022

MENU

MULTIPLE MYELOMA

Navigator - Heather x3661

S1803	Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)

ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

JUNE 2022

MENU

NEUROENDOCRINE

Navigator - Carrie x3621

A021804	A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma

ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

JUNE 2022

MENU

NSCLC

Navigator - Ashton x3611

ADJUVANT / NEOADJUVANT

A081801	Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ALCHEMIST substudy- *Must be enrolled on ALCHEMIST and this substudy prior to start of tx).*
A151216	Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial **(ALCHEMIST)**.
EA5181	**(RT at UPHM and Galesburg)** Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC **(credentialing pending at Glen Oak & Rt-91)**
GO41854	**(Bloomington, Galesburg, Pekin, Peoria, Peru)** A Phase III, Open Label, Randomized Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Patients With Locally Advanced, unresectable Stage III Non-Small Cell Lung Cancer Who Have Not Progressed After Concurrent Platinum-Based Chemoradiation **(SKYSCRAPER-03)**
S1914	**(RT at Glen Oak, UPHM, Galesburg)** Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
S1934 (JIT)	Randomized Phase II Trial of Trimodality +/- Atezolizumab in Resectable Superior Sulcus Non-Small Cell Lung Cancer. **NASSIST** (Neoadjuvant Chemoradiation +/- Immunotherapy Before Surgery for Superior Sulcus Tumors)

METASTATIC - 1st Line

EA5182	Randomized Phase III Study of Combination AZD9291 (osimertinib) and Bevacizumab versus AZD9291 (osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
MK 7684A-003	**(Peoria only)** A Phase 3, Multicenter, Randomized, Double-Blind Study of MK-7684 with Pembrolizumab as a Coformulation (MK-7684A) Versus Pembrolizumab Monotherapy as First Line Treatment for Participants With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer
TH-138	**(Peoria, Bloomington, Galesburg, Pekin)** Phase II Randomized Trial of Carboplatin + Pemetrexed+ Bevacizumab, With or Without Atezolizumab in Stage IV Non-Squamous NSCLC Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked ***(non smokers)***

METASTATIC - 2nd/3rd Line

LUNGMAP	A Master Protocol To Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated NSCLC. (**SUB-STUDIES: S1800D** - *A Phase II/III Study of N-803 (ALT-803) plus Pembrolizumab versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy;* **S1900E** - *A Phase II Study of AMG 510 in Participants With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer)*
MK 7684A-002	**(Peoria only)** A Phase II, Multicenter, Randomized Study to Compare the Efficacy and Safety of MK-7684A or MK-7684A Plus Docetaxel Versus Docetaxel Monotherapy in the Treatment of Participants With Metastatic NSCLC With Progressive Disease After Treatment With a Platinum Doublet Chemotherapy and Immunotherapy.

TH-138	**(Peoria, Bloomington, Galesburg, Pekin)** Phase II Randomized Trial of Carboplatin + Pemetrexed+ Bevacizumab, With or Without Atezolizumab in Stage IV Non-Squamous NSCLC Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked ***(EGFR mutants)***
CANCER CONTROL (NSCLC Only)	
A211901	Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions
A222004	A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia
EAQ202	Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
S1912CD	A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention **(CREDIT)**
S2013	**(Peoria, Bloomington, Galesburg, Pekin, Washington)** Immune Checkpoint Inhibitor Toxicity: A Prospective Observational Study **(I-CHECKIT)**
URCC 21038	**(Peoria Only)** Disparities in Results of ImmuneCheckpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated With anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting
WF-1901	Internet-delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS)

ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

JUNE 2022

MENU

PANCREATIC

Navigator - Carrie x3621

ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

JUNE 2022

MENU

PROSTATE

Navigator - Carrie x3621

	ADJUVANT
GU008	**(RT at Glen Oak, UPHM)** Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE): *Intensifying Treatment for Node Positive Prostate Cancer by Varying the Hormonal Therapy*
GU009	**(RT at Glen Oak, Galesburg, UPHM)** Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation **(PREDICT-RT*)**
GU010	**(RT at UPHM)** Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)
	METASTATIC
64091742PCR0002 / Prevalence	Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer
C2321001	**(Peoria only)** A Phase I Dose Escalation and Expanded Cohort Study of PF-06821497 in the Treatment of Adult Patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) and Follicular Lymphoma (FL)
A031902 / CASPAR	A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer

GU011	**(RT at Glen Oak and UPHM)** A Phase II Double-Blinded, Placebo-Controlled Trial of PROstate OligoMETastatic RadiotHErapy With or Without ANdrogen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean)
S1802	**(RT at Glen Oak & UPHM)** Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

JUNE 2022

MENU

RENAL CELL

Navigator - Carrie x3621

A031704	PD-Inhibitor (nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer (PDIGREE)
MK 6482-011	**(Peoria, Bloomington, Galesburg, Pekin)** An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy

ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

JUNE 2022

MENU

RADIATION TRIALS

Navigator - Jessica x3615

CANCER CONTROL	
WF-1801	A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy
ANAL	
EA2182	**(UPHM and Glen Oak)** A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)
BLADDER	
A032002	**(RT at Glen Oak)** Phase II Randomized Trial of Atezolizumab Versus Atezolizumab and Radiation Therapy for Platinum Ineligible/Refractory Metastatic Urothelial Cancer (ART)
EA8185	**(RT pending at Glen Oak & Rt-91)** Phase 2 Study of Bladder-Sparing Chemoradiation With MEDI4736 (Durvalumab) in Clinical Stage 3, Node Positive Bladder Cancer (INSPIRE)
S1806	**(Glen Oak, UPHM and Galesburg)** Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer
BRAIN	
BN007	**Temporarily Closed (UPHM, Glen Oak, Galesburg)** A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
N0577	**(Glen Oak, RT 91, and UPHM)** Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
BRAIN METS	
A071801	**(UPHM & Glen Oak)** Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared With Fractionated SRS for Resected Metastatic Brain Disease

CCTG CE.7	**(UPHM & Glen Oak)-** A Phase III Trial of Stereotactic Radiosurgery Compared with Whole Brain Radiotherapy (WBRT) for 5-15 Brain Metastases
BREAST	
A011202	*Temporarily Closed* **(Glen Oak, Rt 91, UPHM, Galesburg)** A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in breast Cancer Patients (cT1-3 N1) Who Have Positive Lymph Node Disease After Neoadjuvant Chemotherapy.
BR007	**(Galesburg, Glen Oak, Rt 91, UPHM)** Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer
MA.39	**(Glen Oak and UPHM)** Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
ESOPHAGEAL/GASTRIC	
EA2174	**(Glen Oak, Rt 91, UPHM, Galesburg)** A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
HEAD & NECK	
EA3161	**(Glen Oak, UPH, Galeburg)** A Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
HN005	**(UPHM, Galesburg, Glen Oak)** A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
HN009	(RT at UPHM) Randomized Phase II/III Trial of Radiation With High-Dose Cisplatin (100 mg/m2) Every Three Weeks Versus Radiation With Low-Dose Weekly Cisplatin (40 mg/m2) for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
HODGKIN'S LYMPHOMA	
S1826	**(Glen Oak, Rt-91, UPHM)** A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
MERKEL CELL	
EA6174	**(Glen Oak, UPHM and Galesburg)** A Phase III Randomized Trial Comparing Adjuvant MK3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma

NSCLC	
EA5181	**(UPHM and Galesburg)** Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC **(credentialing pending at Glen Oak)**
S1914	**(Glen Oak, UPHM, Galesburg)** Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
PROSTATE	
GU008	**(RT at Glen Oak, UPHM)** Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE): *Intensifying Treatment for Node Positive Prostate Cancer by Varying the Hormonal Therapy*
GU009	**(RT at Glen Oak, Galesburg, UPHM)** Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation **(PREDICT-RT*)**
GU010	**(RT at UPHM)** Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)
GU011	**(RT at Glen Oak & UPHM)** A Phase II Double-Blinded, Placebo-Controlled Trial of PROstate OligoMETastatic RadiotHErapy With or Without ANdrogen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean)
S1802	**(Glen Oak & UPHM)** Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
WF-1802	**(Glen Oak, Rt-91, UPHM, Galesburg)** Influence of Primary Treatment for Prostate Cancer on Work Experience (PCW)
SCLC	

NRG CC009	**(Glen Oak, UPHM)** - Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer
LU005	**(Glen Oak, UPHM and Galesburg)** Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
S1827	**(Glen Oak, UPHM, Galesburg**) A Randomized Phase III Trial of MRI Surveillance With or Without Prophylactic Cranial Irradiation (PCI) in Small-Cell Lung Cancer

ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

JUNE 2022

MENU

SMALL CELL LUNG CANCER

Navigator - Ashton x3611

NRG CC009	**(RT at Glen Oak, UPHM)** - Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer
GO43104	**(Peoria, Bloomington, Galesburg, Ottawa, Pekin, Peru, Washington)** A Phase III, Randomized, Open-Label, Multicenter Study of Lurbinectedin In Combination With Atezolizumab Compared With Atezolizumab As Maintenance Therapy In Participants With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Followiing First-Line Induction Therapy With Carboplatin, Etoposide and Atezolizumab
LU005	**(RT at Glen Oak, UPHM and Galesburg)** Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
S1827	**(RT at Glen Oak, UPHM, Galesburg)** A Randomized Phase III Trial of MRI Surveillance With or Without Prophylactic Cranial Irradiation (PCI) in Small-Cell Lung Cancer
S1929	Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination With Talazoparib in Patients With SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC) *Tissue screening allowed during induction chemotherapy*

BMS-CA017-078 SCHEMA
Navigator - Carrie x3621

MENU

BMS-986205/placebo tablets have been discontinued.

Figure 1-1: Study Design Schematic



Chemotherapy:
- **GFR ≥ 60 mL/min: standard GC (cisplatin 70 mg/m² D1, gemcitabine 1000 mg/m² D1, D8, 21D cycles**
- **GFR < 60 mL/min: split-dose GC (cisplatin 35 mg/m² D1, D8, gemcitabine 1000 mg/m² D1, D8, 21D cycles**

C2321001 SCHEMA

Contact Disease Specific Navigator

MENU



*50-70% down modulation of H3K27me3

TH-138 (NCCN) SCHEMA
Navigator - Ashton x3611

MENU

Study Design



* Patients with an EGFR exon 19 or 21 mutation must have progression or intolerance of treatment with prior targeted therapy.

US-VEN-207 (ULTRA-V) Schema
Navigator - Heather x3661

MENU

FIGURE 2: PHASE 3 STUDY DESIGN



*BTK-refractory defined as disease progression while on, or within 6 months of the last dose of a BTK inhibitor (e.g., ibrutinib, acalabrutinib, etc)

MK 6482-011 Schema
Navigator - Carrie x3621

MENU



TPX-0005-01 Schema
Contact Disease Site Specific Navigator

MENU

Figure 2. Schema of TPX-0005-01 Study



GO41854 Schema
Navigator - Ashton x3611

MENU



Stratification factors
- ECOG PS (0 vs 1)
- PD-L1 status (<1% vs ≥1%)
- Staging (IIIA vs IIIB or IIIC)
- Histology (squamous vs non-squamous)

Safety run-in
- iDMC review after a minimum of 24 patients (approximately 12 per arm) who have completed first 2 full cycles of study treatment
- Enrollment will not be paused

*For patients whose weight ≥30 kg

A011202 SCHEMA
Navigator Angie x3613

MENU

Schema for patients who pre-register prior to SLN surgery:



Schema for patients who pre-register AFTER surgery* (where SLN surgery was performed but ALND was NOT performed):



*** Patients who are pre-registered after SLN surgery are NOT eligible to enroll onto the Arm Lymphedema Companion Study (A011201-SI1)**

EA5181 SCHEMA
Navigator - Ashton x3611

MENU

Schema



A081801 SCHEMA
Navigator - Ashton x3611

MENU

Schema: 1 cycle = 21 days



S1823 SCHEMA
Navigator - Carrie x3621

MENU

SCHEMA



* Patients and providers will not have knowledge of the results of the miRNA 371 analysis.

NRG CC003 SCHEMA
Navigator - Jessica x3615

MENU

Histologic proof or unequivocal cytologic proof of SCLC

STEP 1 REGISTRATION

STEP 2 REGISTRATION/RANDOMIZATION

Baseline neurocognitive assessment: HVLT-R, TMT, COWA *(required)*

Note: Neurocognitive assessments must be uploaded prior to Step 2 Registration and can be uploaded at the time of Step 1 Registration.

STRATIFICATION

Stage: Limited vs. Extensive
Age: < 60 years old vs. ≥ 60 years old
Planned Concurrent Memantine Use: Yes vs. No

Arm 1

PCI Alone (25 Gy in 10 Fractions)

Arm 2

PCI with Hippocampal Avoidance using IMRT (25 Gy in 10 Fractions)

Merck 7339-003 / LYNK-003 SCHEMA
Navigator -Carrie x3621

MENU



NRG BN007
Navigator -Carrie x3621

MENU

STEP 1 REGISTRATION

Central Pathology Review for confirmation of glioblastoma (GBM) histology and of unmethylated MGMT promotor status

NOTE: Tumor tissue must be received and central review confirmation completed before STEP 2 registration can occur.

↓

STEP 2 REGISTRATION

STRATIFY

- Recursive partioning analysis (RPA) (III vs IV vs V)
- Intent to use Optune (yes vs no)

RANDOMIZE (1:1)

Arm 1	**Arm 2**
Radiation Therapy plus Concomitant temozolomide plus Adjuvant temozolomide (Optune allowed)	Radiation Therapy plus Concomitant ipilimumab and nivolumab plus Adjuvant ipilimumab and nivolumab (Optune not allowed)

S1929
Navigator -Ashton x3611

MENU



EA8185
Navigator -Carrie x3621

MENU

Schema



M15-954
Navigator -Heather x3661

MENU



FU = follow up; HSCT = hematopoietic stem cell transplant; IPSS-R = Revised International Prognostic Scoring System; LSFD = last subject first dose; MDS = myelodysplastic syndrome; QD = once daily

EA2176
Navigator -Carrie x3621

MENU



1. Randomization is 1:2 (A:B).
2. For this protocol, all patients, including those who discontinue protocol therapy early, will be followed for response until disease progression, even if non-protocol therapy is initiated, and for survival every 3 months for two years from the date of randomization. All patients must also be followed through completion of all protocol therapy.



BICR=blinded independent central review; DMC=Data Monitoring Committee; IMDC=International Metastatic Renal Cell Carcinoma Database Consortium; QD=once daily; RCC=renal cell carcinoma; ROW=rest of world; TKI=tyrosine kinase inhibitor; US=United States; VEGF=vascular endothelial growth factor.

A031901
Navigator -Carrie x3621

MENU

Schema

Cycle definition is based on ICI cycle length



* ICI agents include pembrolizumab, nivolumab, atezolizumab, durvalumab and avelumab

Patients will be followed for 5 years or until death or withdrawal of consent, whichever occurs first.

Schema


RANDOMIZE
ARM 1
Text-Message Reminder (TMR)
ARM 2
Motivational Interviewing (MI) Counseling
ARM 3
TMR + MI
ARM 4
Enhanced Usual Care

WF-1901
Navigator -Courtney x3660

MENU



EA3161
Navigator -Ashton x3611

MENU

Schema



Accrual Goal: 744

1. Submit tissue for PD-L1 testing.
2. Cycle length = 28 days
3. Patients who were randomized to observation will be offered the option to cross over if they have clearly documented progression by the RECIST criteria and tissue-proven progression within 12 months from the end of cisplatin/radiation therapy.

EA5182
Navigator -Ashton x3611

MENU

Schema



Accrual Goal = 300 patients
Cycle = 3 weeks (21 days)

EA2174
Navigator -Carrie x3621

MENU

Schema



N=278

1. Please reference Section 5.1 for treatment dosing specifics.
2. Optional Diffusion weighted imaging-MRI (DWI-MRI) should be obtained at step 1 baseline and 2-3 weeks after initiation of protocol treatment.

A031902
Navigator -Carrie x3621

MENU

Schema

PK Substudy (Dose Finding Portion) Only



Phase III (Double-Blinded, Placebo-Controlled) Portion



For all patients, treatment is to continue until disease progression or unacceptable adverse event. Patients will be followed for 5 years or until death, whichever comes first.

Please refer to the full protocol text for a complete description of the eligibility criteria and treatment plan.

S1806
Navigator -Carrie x3621

MENU



A031704
Navigator -Carrie x3621

MENU

Schema

1 cycle = 28 days



GU008
Navigator -Carrie x3621

MENU



NRG-CC009
Navigator -Jessica x3615

MENU

NRG-CC009
SCHEMA

STEP 1 REGISTRATION

↓

STEP 2 REGISTRATION/RANDOMIZATION

Baseline neurocognitive function (NCF) tests: HVLT-R, TMT, COWA (*required*)
Note: NCF testing scores must be uploaded into Rave prior to Step 2 Registration and can be uploaded at the time of Step 1 Registration

STRATIFY
Disease-Specific Graded Prognostic Assessment (DS-GPA)[2]:
1. 0.5-2.0
2. 2.5-4.0

Prior exposure to NCF testing on SWOG S1827[3]:
1. Yes
2. No

RANDOMIZE[1]

↓ ↓

Arm 1	**Arm 2**
Stereotactic radiosurgery (SRS)	Whole brain radiotherapy with hippocampal avoidance (HA-WBRT)+ Memantine

[1]Randomization is 1:1

GU009
Navigator -Carrie x3621

MENU

NRG-GU009
SCHEMA

STEP 1 REGISTRATION
Completion of Step 1 eligibility checklist in OPEN and then submission of tissue for Decipher analysis
Note: Decipher analysis results must be completed before **Step 2 randomization** can occur. If Decipher results have already been obtained, in lieu of tissue, after completion of Step 1 eligibility checklist in OPEN, the original Decipher report must be submitted to Decipher Biosciences for validation (see Decipher Analysis information at the end of section 3.0).

STEP 2 RANDOMIZATION
Decipher ≤ 0.85

DE-INTENSIFICATION STUDY
STRATIFY

- Decipher Score (Low/Int v High*)
- Boost type (EBRT vs. Brachy)
- Pelvic Treatment (Yes/No)
- ACE-27 Comorbidity (0/1 vs 2/3)**

RANDOMIZE 1:1

Arm 1
RT
+
24 mos ADT

Arm 2
RT
+
12 mos ADT

STEP 2 RANDOMIZATION
Decipher > 0.85 or Node Positive

INTENSIFICATION STUDY
STRATIFY

- Boost type (EBRT vs. Brachy)
- Pelvic Treatment (Yes/No)
- Nodal Status (Positive/Negative)

RANDOMIZE 1:1

Arm 3
RT
+
24 mos ADT

Arm 4
RT
+
24 mos ADT
+24 mos Apalutamide

* Low/Intermediate = Decipher < 0.6 and High = Decipher 0.6-0.85
** http://comogram.org/assets/files/ace-27_ctr_ver_rtog_web.pdf
Note: A radiation treatment approach change post registration involving the pelvic lymph node treatment or prostate boost type stratification factors will result in a protocol deviation.
RT = radiation therapy; ADT = androgen deprivation therapy

MK 7684A-002
Navigator -Ashton x3611

MENU



Stratification
- ECOG performance status (0 vs 1)
- Prior anti-PD-1/PD-L1 mAb (immediate prior treatment vs not immediate prior treatment)
- PD-L1 TPS (<50% vs ≥50%)

[a] See full list of inclusion and exclusion criteria in Section 5.1 and Section 5.2.
[b] MK-7684 and pembrolizumab are co-formulated and referred to in this protocol as MK-7684A. The components of MK-7684A are MK-7684 200 mg/pembrolizumab 200 mg.
[c] Treatment with MK-7684A may continue until a discontinuation criteria is met, or completion of 35 cycles.
[d] Treatment with docetaxel may continue until a discontinuation criterion is met or as per approved local label.

MK 7684A-003
Navigator -Ashton x3611

MENU



BR007
Navigator -Angie Earles x3613

MENU



NRG-GY023
Navigator -Angie Earles x3613

MENU



*Non-platinum single agent chemotherapy includes weekly paclitaxel, topotecan or pegylated liposomal doxorubicin (PLD). There can be no deviance from the prescribed regimens, e.g. addition of bevacizumab or other agents.

Randomization is 1:2:2:2

EA9152
Navigator -Heather Thulean x3661

MENU

Schema



Phase II Accrual Goal: 56 patients (including the patients from the Phase I arm with the MTD dose)

1. If patient demonstrates CR or Cri at day 28 or day 56 bone marrow biopsies, they may continue on combination therapy or proceed to HSCT if deemed fit for transplant and advised by treating physician. Patient may proceed to HSCT at any point at treating physician's discretion (if not day 28 or 56).
2. Patients will be stratified by immunophenotype: "B-cell ALL" vs. "T-cell ALL".
3. If patient does not demonstrate any signs of progression, they may continue on combination therapy as long as they are receiving benefit per treating physician. Patients, if in CR/Cri by the end of cycle 2 may continue on combination or single agent venetoclax at the discretion of the treating physician.
4. Bone marrow and peripheral blood specimens must be submitted for mandatory central review.

S1912CD
Navigator -Courtney Brown x3660

MENU

SCHEMA

Patient and spouse caregiver

Completion of baseline forms



In order to participate, CCD Research sites must complete the **S1912CD** Site Implementation Survey and upload the completion certificate to the CTSU Regulatory Portal as described in Section 13.4.
* Consumer Education and Training Services (CENTS)
** Patient Advocate Foundation (PAF)

GO43104
Navigator -Ashton Todd 3611

MENU



S2013
Navigator - Kelsey Fay x3618

MENU

SCHEMA



S2011
Navigator -Carrie Geoffroy x3621

MENU



A222004
Navigator -Kelsey Fay x3618

MENU



Treatment will continue for up to 4 weeks, unless the patient declines therapy or has unacceptable adverse events.

EAQ202
Navigator -Courtney Brown x3660

MENU

Schema



Eligibility:	**Randomization:**	**Domain Rank:**
-Age 18 to 39 -Within 12 weeks of diagnosis -Performance Status 0-3 -Any stage of cancer -Favorable prognosis	Stratified by sex, race, ethnicity, and age (emerging adults 18-25-year-old vs young adults 26-39-year-old)	Participant Ranks Domain by personal priority at each time point **Fixed PRO:** PROMIS Global, PROMIS standard AYA 5 domains, Common Items **Choice PRO:** PROMIS Global, 5 ranked AYA domains, Common Items

Accrual Goal = 400

GU010
Navigator -Jessica Jones x3615

MENU

SCHEMA



*For Escalated RT boost definition see Section 5.2 Establishing Treatment Approaches
**Randomization is 1:1
RT = radiation therapy; SBRT=stereotactic body radiotherapy; ADT =androgen deprivation therapy

BN011
Navigator -Carrie Geoffroy x3621

MENU

NRG-BN011
SCHEMA

STEP 1 REGISTRATION

Central Pathology Review for confirmation of glioblastoma (GBM) histology and of methylated MGMT promotor status

NOTE: Tumor tissue must be received and central review confirmation completed before STEP 2 registration can occur.*

↓

STEP 2 REGISTRATION

STRATIFY

- Recursive partitioning analysis (RPA) (III vs IV vs V)
- Intent to use tumor treating fields (Optune) (yes vs no)

RANDOMIZE (1:1)

Arm 1	**Arm 2**
Radiation Therapy with Concomitant and Adjuvant Temozolomide	Radiation Therapy with Concomitant and Adjuvant Lomustine and Temozolomide

See Section 5.1 for agent treatment details and Section 5.2 for radiation therapy details.

*Patients with unmethylated MGMT may be considered for enrollment on NRG-BN007. Please see Section 10.2 for additional information.

A032002
Navigator -Carrie Geoffroy x3621

MENU

Alliance A032002

Schema

1 Cycle = 21 Days



Treatment is to continue until disease progression or unacceptable adverse event. Patients will be followed for 3 years or until death, whichever comes first.

Schema



* Target quit date will be 8 weeks following enrollment.
** NCI's Smokefree.TXT messages will start 2 weeks before quit date and extend for 4 weeks after quit date.
*** Quit date must be within 8 weeks of receiving the *Clearing The Air* cessation booklet

Please refer to the full protocol text for a complete description of the eligibility criteria and intervention plan.

NSABP C-14
Navigator -Carrie x3621

MENU



GU011
Navigator -Carrie x3621

MENU

NRG-GU011
SCHEMA

Recurrent Oligometastatic Prostate Cancer (detected by PET) after RT to Prostate or Radical Prostatectomy +/- Post-Operative Radiotherapy

STRATIFY

- Extrapelvic node(s) only vs Bone +/- node(s) [pelvic/extrapelvic]
- PSA Doubling Time <12 mos vs ≥ 12mos
- Fluciclovine PET vs PSMA PET

RANDOMIZE*

↓ ↓

Arm 1	**Arm 2**
SABR + blinded placebo** for 6 months	SABR + blinded relugolix** for 6 months

*Randomization is 1:1

** Monitor according to Test Schedule; see Sections 4.2, 4.3, and 5.3.1 for progression. Salvage ADT should be delayed until metastatic progression by conventional imaging.

A041702
Navigator -Heather x3661

MENU

A041702

SCHEMA



Patients will be followed for 10 years from study registration (Step 1) or until death, whichever comes first. **Please refer to the full protocol text for a complete description of the eligibility criteria and treatment plan**

A032001
Navigator -Carrie x3621

MENU

Schema

1 Cycle = 28 Days



*Randomization is to occur 3-10 weeks after last dose of 1st-line treatment

Stratification:

- Best response to 1st-line chemo (SD vs PR vs CR)
- Visceral metastases: present versus absent

Please refer to the full protocol text for a complete description of the eligibility criteria and treatment plan.

NRG GI008
Navigator -Carrie x3621

MENU

Figure 1.
NRG-GI008 SCHEMA



*Patients with completely resected stages II or IIIC colon cancer who are ctDNA +ve as determined by a Signatera™ ctDNA test performed outside of the trial through routine clinical care and who otherwise meet all eligibility criteria for Step 1-Registration are eligible for enrollment into Cohort B.

**Patients in Cohort A (Arm 2) who develop a ctDNA +ve assay during serial monitoring may transition to the ctDNA+ve cohort (Cohort B) and undergo a second randomization.

URCC 21038
Navigator -Hannah x3628

MENU

STUDY SCHEMA



NRG- HN009
Navigator -Ashton x3611

MENU

For patients with oropharyngeal cancer (OPC) or cancer of unknown primary (CUP):
Local p16 determination by immunohistochemistry is required.

For patients with laryngeal and hypopharyngeal primaries:
Analysis of p16 status is **not required.**

↓

STRATIFY

- Zubrod (ECOG) performance status: 0 vs. 1
- Smoking status: ≤ 10 pack-year vs. > 10 pack-year history
- T stage: T0-3 vs. T4
- Age: ≤ 50 vs. > 50 years

RANDOMIZE (1:1 in each cohort)

↓

Non-OPC/p16-negative OPC Cohort

Arm 1: IMRT/IMPT + High-dose cisplatin Q 3 weeks

Arm 2: IMRT/IMPT + Low-dose cisplatin weekly

↓

p16-positive OPC/CUP Cohort

Arm 3: IMRT/IMPT + High-dose cisplatin Q 3 weeks

Arm 4: IMRT/IMPT + Low-dose cisplatin weekly

BMS CA224098
Navigator -Carrie x3621

MENU

Key Eligibility Criteria

- ≥ 18 Years of Age
- Completely Resected Melanoma
- Stage IIIA (>1 mm tumor in LN), Stage IIIB/C/D, or Stage IV NED Melanoma
  - No prior immuno-oncology agents
  - ECOG Performance Status ≤ 1
  - Submission of FFPE tissue block or 20 unstained slides from surgical/biopsy specimen within 3 months of randomization.



Stratification[a]
- AJCC v8 stage
- Geographic Region

Maximum treatment duration (1 year from first dose or maximum of 13 doses) [§]

[§] All participants will be treated until recurrence of disease (except melanoma in situ), unacceptable toxicity, participant withdrawal of consent, or a maximum duration of 1 year from first-dose (maximum of 13 doses), whichever occurs first.
* Participants will be followed until death, lost to follow-up, withdrawal of consent, conclusion of the study, or a minimum of 6 years.

Abbreviations: AJCC v8, American Joint Committee on Cancer, version 8; ECOG, Eastern Cooperative Oncology Group; FDC, fixed dose combination; FFPE, formalin-fixed paraffin-embedded; LN, lymph node; NED, no evidence of disease; ROW, rest of the world; Q4W, every 4 weeks.

Schema



All patients will receive oxaliplatin on both phases of the trial. Further, for all patients the 17th week of study drug will be a tapering period.

* Additional patients will be recruited to the Phase III trial. The most promising dose of duloxetine will be determined after initial Phase II, and this dose will be used for Phase III for patients randomized to the duloxetine arm.